05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Bioavailability enhancing molecular complex as an intermediate product in the manufacture of pharmaceuticals for the treatment of migraines, neurological disorders and central nervous system disorders
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Bioavailability enhancing molecular complex as an intermediate product in the manufacture of pharmaceuticals for the treatment of migraines, neurological disorders and central nervous system disorders
4.
PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE
This disclosure relates to pharmaceutical compositions comprising bupropion and cysteine, and pharmaceutical dosage forms comprising bupropion and cysteine. The disclosure also relates to molecular complexes of bupropion and cysteine. These compositions and dosage forms may have improved stability of bupropion.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
This disclosure relates to pharmaceutical compositions comprising bupropion and cysteine, and pharmaceutical dosage forms comprising bupropion and cysteine. The disclosure also relates to molecular complexes of bupropion and cysteine. These compositions and dosage forms may have improved stability of bupropion.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Polymorph forms of reboxetine, and their therapeutic uses, are described herein. Also described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
05 - Produits pharmaceutiques, vétérinaires et hygièniques
16 - Papier, carton et produits en ces matières
35 - Publicité; Affaires commerciales
38 - Services de télécommunications
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, depression, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss.
(2) Printed educational materials in the field of migraines. (1) Promoting public awareness of migraines.
(2) Providing an on-line forum for patients and doctors to communicate and discuss depression and treatments for depression.
(3) Consulting services in the field of health relating to pharmaceuticals; Providing health information relating to pharmaceuticals; Providing health information relating to pharmaceuticals via a website; Providing medical information relating to pharmaceuticals via a website; Providing news and information in the field of medicine relating to pharmaceuticals; Providing on-line information, news and commentary in the field of health and wellness relating to pharmaceuticals; Providing health information; providing health information via a website; providing medical information via a website; providing medical information in the field of depression and treatments for depression; providing mental health information via a website; providing mental health and wellness information; providing news and information in the field of medicine; providing news and information in the field of mental health about depression and treatments for depression; providing on-line information, news and commentary in the field of health and wellness relating to depression and treatments for depression; Providing healthcare information in the field of migraines; Providing healthcare information in the field of migraines via a website.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
16 - Papier, carton et produits en ces matières
35 - Publicité; Affaires commerciales
38 - Services de télécommunications
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, depression, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss. Printed educational materials in the field of migraines. Promoting public awareness of migraines. Providing an on-line forum for patients and doctors to communicate and discuss depression and treatments for depression. Consulting services in the field of health relating to pharmaceuticals; Providing health information relating to pharmaceuticals; Providing health information relating to pharmaceuticals via a website; Providing medical information relating to pharmaceuticals via a website; Providing news and information in the field of medicine relating to pharmaceuticals; Providing on-line information, news and commentary in the field of health and wellness relating to pharmaceuticals; Providing health information; providing health information via a website; providing medical information via a website; providing medical information in the field of depression and treatments for depression; providing mental health information via a website; providing mental health and wellness information; providing news and information in the field of medicine; providing news and information in the field of mental health about depression and treatments for depression; providing on-line information, news and commentary in the field of health and wellness relating to depression and treatments for depression; Providing healthcare information in the field of migraines; Providing healthcare information in the field of migraines via a website.
45 - Services juridiques; services de sécurité; services personnels pour individus
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Providing a website featuring information on managing behavioral symptoms associated with Alzheimer’s disease Providing information in the field of Alzheimer’s disease
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Management of pharmacy benefit programs featuring a medical benefit co-pay card; Financial administration of patient assistance eligibility programs featuring a pharmacy benefit co-pay card; providing financial assistance in the form of prepaid co-pay cards to patients for medical benefits; mail-order pharmacy services; healthcare benefit information services Providing personal support services for caregivers, partners, wives and husbands of the chronically ill and/or disabled, namely, companionship and emotional support
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Management of pharmacy benefit programs featuring a medical benefit co-pay card; Financial administration of patient assistance eligibility programs featuring a pharmacy benefit co-pay card; providing financial assistance in the form of prepaid co-pay cards to patients for medical benefits; mail-order pharmacy services; healthcare benefit information services Providing personal support services for caregivers, partners, wives and husbands of the chronically ill and/or disabled, namely, companionship and emotional support
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Management of pharmacy benefit programs featuring a medical benefit co-pay card; Financial administration of patient assistance eligibility programs featuring a pharmacy benefit co-pay card; providing financial assistance in the form of prepaid co-pay cards to patients for medical benefits; mail-order pharmacy services; healthcare benefit information services Providing personal support services for caregivers, partners, wives and husbands of the chronically ill and/or disabled, namely, companionship and emotional support
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated and pharmaceutical preparations for the treatment and prevention of migraines; medicated and pharmaceutical preparations for the treatment and prevention of neurological disorders.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Medicated and pharmaceutical preparations for the treatment and prevention of migraines; medicated and pharmaceutical preparations for the treatment and prevention of neurological disorders.
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
The present invention relates a method of treating attention-deficit/hyperactivity disorder (ADHD), wherein the patient suffers from mood disorders and/or anxiety. More specifically, the present invention is directed to a method of using a carbamate compound alone or in combination with other medications, for the treatment of ADHD.
This disclosure relates to pharmaceutical compositions comprising bupropion and cysteine, and pharmaceutical dosage forms comprising bupropion and cysteine. The disclosure also relates to molecular complexes of bupropion and cysteine. These compositions and dosage forms may have improved stability of bupropion.
Described herein are methods of treating fibromyalgia, comprising administering esreboxetine to a human being in need thereof. Esreboxetine may also be used in the manufacture of a medicament for the treatment of fibromyalgia.
This disclosure relates to microparticles containing bupropion, e.g., microparticles having a particle diameter of about 50 μm to about 100 μm. These microparticles may be included in pharmaceutical compositions and/or dosage forms for treatment of various disease, such as depression.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Prescription medicated and pharmaceutical preparations for the treatment and prevention of migraines; prescription medicated and pharmaceutical preparations for the treatment and prevention of neurological disorders.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Prescription medicated and pharmaceutical preparations for the treatment and prevention of migraines; prescription medicated and pharmaceutical preparations for the treatment and prevention of neurological disorders.
32.
COMBINATION DOSAGE FORMS AND ADMINISTRATION THEREOF
This disclosure relates to methods of administering bupropion, such as S-bupropion or R-bupropion, in conjunction with tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to a human being. Dosage forms, drug delivery systems, and methods related to tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine and bupropion, such as S-bupropion or R-bupropion, are also disclosed.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Disclosed herein is a method of treating migraine in patients with a history of inadequate response to prior migraine treatments comprising: selecting a patient who, for at least the past month: 1) has had 2 to 8 migraines per month, and 2a) according to the patient, is never or rarely comfortable enough with the patient's migraine medication to be able to plan daily activities, 2b) according to the patient, after taking migraine medication, the patient never or rarely feels in control of the patient's migraines enough so that the patient feels there will be no disruption in the patient's daily activities, 2c) has an mTOQ-4 score of 0, and/or 2d) has a history of depression; and administering a combination of 20 mg of meloxicam and 10 mg of rizatriptan to the patient during a migraine attack.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Described herein is a method of treating a neurological or psychiatric condition comprising administering a methylenedioxy derived designer drug or a benzofuran derived designer drug, to a mammal in need thereof. Also described herein use of a compound in the manufacture of a medicament for treating a neurological or psychiatric condition, wherein the compound is a methylene derived designer drug or a benzofuran derived designer drug.
A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/49 - Dérivés du cinchonane, p. ex. quinine
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan.
Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
This disclosure relates to microparticles containing bupropion, e.g., microparticles having a particle diameter of about 50 μm to about 100 μm. These microparticles may be included in pharmaceutical compositions and/or dosage forms for treatment of various disease, such as depression.
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p. ex. chorée, dyskinésie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated and pharmaceutical preparations for use in connection with humans, namely, those for the treatment, prevention, and diagnosis of pain and related conditions.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated and pharmaceutical preparations for use in connection with humans, namely, those for the treatment, prevention, and diagnosis of pain and related conditions.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
35 - Publicité; Affaires commerciales
36 - Services financiers, assurances et affaires immobilières
38 - Services de télécommunications
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, depression, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss Downloadable cloud-based software for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders; Downloadable software in the nature of a mobile application for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders Printed educational materials in the field of migraines Promoting public awareness of migraines; providing business management of pharmacy benefit programs that feature a medical benefit co-pay card; financial management of pharmacy benefit programs for others that feature a medical benefit co-pay card; Financial administration of patient financial assistance eligibility programs featuring a pharmacy benefit co-pay card; providing financial assistance in the form of prepaid co-pay cards to patients for use in receiving medical benefits Providing an on-line forum for patients and doctors to communicate and discuss depression and treatments for depression Consulting services in the field of health relating to pharmaceuticals; Providing health information relating to pharmaceuticals; Providing health information relating to pharmaceuticals via a website; Providing medical information relating to pharmaceuticals via a website; Providing news and information in the field of medicine relating to pharmaceuticals; Providing on-line information, news and commentary in the field of health and wellness relating to pharmaceuticals; Providing health information; providing health information via a website; providing medical information via a website; providing medical information in the field of depression and treatments for depression; providing mental health information via a website; providing mental health and wellness information; providing news and information in the field of medicine; providing news and information in the field of mental health about depression and treatments for depression; providing on-line information, news and commentary in the field of health and wellness relating to depression and treatments for depression; Providing healthcare information in the field of migraines; Providing healthcare information in the field of migraines via a website
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
35 - Publicité; Affaires commerciales
36 - Services financiers, assurances et affaires immobilières
38 - Services de télécommunications
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, depression, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss Downloadable cloud-based software for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders; Downloadable software in the nature of a mobile application for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders Printed educational materials in the field of migraines Promoting public awareness of migraines; providing business management of pharmacy benefit programs that feature a medical benefit co-pay card financial management of pharmacy benefit programs for others that feature a medical benefit co-pay card; Financial administration of patient financial assistance eligibility programs featuring a pharmacy benefit co-pay card; providing financial assistance in the form of prepaid co-pay cards to patients for use in receiving medical benefits Providing an on-line forum for patients and doctors to communicate and discuss depression and treatments for depression Consulting services in the field of health relating to pharmaceuticals; Providing health information relating to pharmaceuticals; Providing health information relating to pharmaceuticals via a website; Providing medical information relating to pharmaceuticals via a website; Providing news and information in the field of medicine relating to pharmaceuticals; Providing on-line information, news and commentary in the field of health and wellness relating to pharmaceuticals; Providing health information; providing health information via a website; providing medical information via a website; providing medical information in the field of depression and treatments for depression; providing mental health information via a website; providing mental health and wellness information; providing news and information in the field of medicine; providing news and information in the field of mental health about depression and treatments for depression; providing on-line information, news and commentary in the field of health and wellness relating to depression and treatments for depression; Providing healthcare information in the field of migraines; Providing healthcare information in the field of migraines via a website
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Disclosed herein are methods of improving cognitive function, comprising administering solriamfetol to a human patient experiencing excessive daytime sleepiness associated with obstructive sleep apnea.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Disclosed herein is a method of treating migraine in patients with a history of inadequate response to prior migraine treatments comprising: selecting a patient who, for at least the past month: 1) has had 2 to 8 migraines per month, and 2a) according to the patient, is never or rarely comfortable enough with the patient's migraine medication to be able to plan daily activities, 2b) according to the patient, after taking migraine medication, the patient never or rarely feels in control of the patient's migraines enough so that the patient feels there will be no disruption in the patient's daily activities, 2c) has an mTOQ-4 score of 0, and/or 2d) has a history of depression; and administering a combination of meloxicam and rizatriptan to the patient during a migraine attack.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Described herein are methods for the administration of reboxetine, or a pharmaceutically acceptable salt thereof, to a human being in need thereof, resulting in a first maximum plasma concentration and a second maximum plasma concentration, wherein the two maxima are separated by a time period of about 2 hours to about 6 hours.
The present invention relates to a method of treating an orphan disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds, particularly solriamfetol and even more particularly solriamfetol hydrochloride.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated and pharmaceutical preparations for the treatment and prevention of migraines; Medicated and pharmaceutical preparations for the treatment and prevention of neurological disorders
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
35 - Publicité; Affaires commerciales
36 - Services financiers, assurances et affaires immobilières
38 - Services de télécommunications
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Medicated and pharmaceutical preparations for use in
connection with humans, namely, antibiotics, antifungals
preparations, antivirals, and for treatment of
cardiovascular, dermatological, respiratory, central nervous
system, gastro-intestinal diseases, autoimmune, metabolic,
endocrine, musculo-skeletal, genitourinary, tissue and
organ, ocular, ophthalmological, immune system, pain,
kidney, urological, and bone diseases and disorders and for
the treatment of fibromyalgia, smoking cessation,
narcolepsy, excessive daytime sleepiness, alzheimer's
disease agitation, migraine, depression, diabetes,
hypertension, skin disorders, allergies, asthma, obesity,
and hair loss. Downloadable cloud-based software for the purpose of
tracking, managing and storing information related to
medications and medication compliance, patient health,
wellness and symptoms, and patient diseases and disorders;
downloadable software in the nature of a mobile application
for the purpose of tracking, managing and storing
information related to medications and medication
compliance, patient health, wellness and symptoms, and
patient diseases and disorders. Printed educational materials in the field of migraines. Promoting public awareness of migraines. Management of pharmacy benefit programs featuring a medical
benefit co-pay card (term considered too vague by the
International Bureau pursuant to Rule 13 (2) (b) of the
Regulations); financial administration of patient assistance
eligibility programs featuring a pharmacy benefit co-pay
card; providing financial assistance in the form of prepaid
co-pay cards to patients for medical benefits. Providing an on-line forum for patients and doctors to
communicate and discuss depression and treatments for
depression. Consulting services in the field of health relating to
pharmaceuticals; providing health information relating to
pharmaceuticals; providing health information relating to
pharmaceuticals via a website; providing medical information
relating to pharmaceuticals via a website; providing news
and information in the field of medicine relating to
pharmaceuticals; providing on-line information, news and
commentary in the field of health and wellness relating to
pharmaceuticals; providing health information; providing
health information via a website; providing medical
information via a website; providing medical information in
the field of depression and treatments for depression;
providing mental health information via a website; providing
mental health and wellness information; providing news and
information in the field of medicine; providing news and
information in the field of mental health about depression
and treatments for depression; providing on-line
information, news and commentary in the field of health and
wellness relating to depression and treatments for
depression; providing information in the field of migraines
(term considered too vague by the International Bureau
pursuant to Rule 13 (2) (b) of the Regulations); providing
information in the field of migraines via a website (term
considered too vague by the International Bureau pursuant to
Rule 13 (2) (b) of the Regulations).
52.
Pharmaceutical compositions comprising bupropion and cysteine
This disclosure relates to pharmaceutical compositions comprising bupropion and cysteine, and pharmaceutical dosage forms comprising bupropion and cysteine. The disclosure also relates to molecular complexes of bupropion and cysteine. These compositions and dosage forms may have improved stability of bupropion.
A61K 9/24 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue en doses unitaires constituées de couches ou feuilletées
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Prescription medicated and pharmaceutical preparations for the treatment and prevention of migraines; prescription medicated and pharmaceutical preparations for the treatment and prevention of neurological disorders
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
Disclosed herein are methods of treating attention-deficit/hyperactivity disorder (ADHD), major depressive disorder (MDD), binge eating disorder (BED), or shift work disorder (SWD) in human beings, such as in adult human beings, by administering solriamfetol to a human being who is suffering from ADHD, MDD, BED, or SWD. The solriamfetol may be administered in the morning, such as within one hour of awakening. In some embodiments, the solriamfetol is administered more than 9 hours before expected bedtime.
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss.
60.
SOLRIAMFETOL FOR TREATING COGNITIVE IMPAIRMENT IN A SUBJECT WITH IMPAIRED COGNITION ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA AND EXCESSIVE DAYTIME SLEEPINESS
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to enhance one or more cognitive function in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness and to treat one or more cognitive impairment in such a patient.
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss
63.
METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION
This disclosure relates to methods administering bupropion, such as S-bupropion or R-bupropion, in conjunction with tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to a human being. Dosage forms, drug delivery systems, and methods related to tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine and bupropion, such as S-bupropion or R-bupropion, are also disclosed.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
64.
METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE
The present invention provides methods for amelioration of biomarkers associated with cardiovascular risk with (R)-2-amino-3-phenylpropyl carbamate (APC).
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss.
Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as an enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
09 - Appareils et instruments scientifiques et électriques
Produits et services
Downloadable cloud-based software for the purpose of
tracking, managing and storing information related to
medications and medication compliance, patient health,
wellness and symptoms, and patient diseases and disorders;
downloadable software in the nature of a mobile application
for the purpose of tracking, managing and storing
information related to medications and medication
compliance, patient health, wellness and symptoms, and
patient diseases and disorders.
71.
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
35 - Publicité; Affaires commerciales
36 - Services financiers, assurances et affaires immobilières
38 - Services de télécommunications
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, depression, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss.
(2) Downloadable cloud-based software for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders; downloadable software in the nature of a mobile application for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders.
(3) Printed educational materials in the field of migraines. (1) Promoting public awareness of migraines.
(2) Management of pharmacy benefit programs featuring a medical benefit co-pay card (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); financial administration of patient assistance eligibility programs featuring a pharmacy benefit co-pay card; providing financial assistance in the form of prepaid co-pay cards to patients for medical benefits.
(3) Providing an on-line forum for patients and doctors to communicate and discuss depression and treatments for depression.
(4) Consulting services in the field of health relating to pharmaceuticals; providing health information relating to pharmaceuticals; providing health information relating to pharmaceuticals via a website; providing medical information relating to pharmaceuticals via a website; providing news and information in the field of medicine relating to pharmaceuticals; providing on-line information, news and commentary in the field of health and wellness relating to pharmaceuticals; providing health information; providing health information via a website; providing medical information via a website; providing medical information in the field of depression and treatments for depression; providing mental health information via a website; providing mental health and wellness information; providing news and information in the field of medicine; providing news and information in the field of mental health about depression and treatments for depression; providing on-line information, news and commentary in the field of health and wellness relating to depression and treatments for depression; providing information in the field of migraines (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); providing information in the field of migraines via a website (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations).
75.
METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION
This disclosure relates to methods administering bupropion, such as S-bupropion or R-bupropion, in conjunction with tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to a human being. Dosage forms, drug delivery systems, and methods related to tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine and bupropion, such as S-bupropion or R-bupropion, are also disclosed.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
09 - Appareils et instruments scientifiques et électriques
Produits et services
(1) Downloadable cloud-based software for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders; downloadable software in the nature of a mobile application for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders.
Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated and pharmaceutical preparations for use in
connection with humans, namely, antibiotics, antifungals
preparations, antivirals, and for treatment of
cardiovascular, dermatological, respiratory, central nervous
system, gastro-intestinal diseases, autoimmune, metabolic,
endocrine, musculo-skeletal, genitourinary, tissue and
organ, ocular, ophthalmological, immune system, pain,
kidney, urological, and bone diseases and disorders and for
the treatment of fibromyalgia, smoking cessation,
narcolepsy, excessive daytime sleepiness, alzheimer's
disease agitation, migraine, depression, diabetes,
hypertension, skin disorders, allergies, asthma, obesity,
and hair loss.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicated and pharmaceutical preparations for use in
connection with humans, namely, antibiotics, antifungals
preparations, antivirals, and for treatment of
cardiovascular, dermatological, respiratory, central nervous
system, gastro-intestinal diseases, autoimmune, metabolic,
endocrine, musculo-skeletal, genitourinary, tissue and
organ, ocular, ophthalmological, immune system, pain,
kidney, urological, and bone diseases and disorders and for
the treatment of fibromyalgia, smoking cessation,
narcolepsy, excessive daytime sleepiness, alzheimer's
disease agitation, migraine, depression, diabetes,
hypertension, skin disorders, allergies, asthma, obesity,
and hair loss.
Described herein are methods of treating narcolepsy with cataplexy or ADHD, comprising administering mazindol to a human being in need thereof. Mazindol may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy or ADHD. Also disclosed herein are kits comprising a pharmaceutical composition comprising mazindol and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy or ADHD in a human being.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
38 - Services de télécommunications
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
36 - Services financiers, assurances et affaires immobilières
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Promoting public awareness of migraines Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, depression, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss Providing an on-line forum for patients and doctors to communicate and discuss depression and treatments for depression Downloadable cloud-based software for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders; Downloadable software in the nature of a mobile application for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders Printed educational materials in the field of migraines Management of pharmacy benefit programs featuring a medical benefit co-pay card; Financial administration of patient assistance eligibility programs featuring a pharmacy benefit co-pay card; providing financial assistance in the form of prepaid co-pay cards to patients for medical benefits Consulting services in the field of health relating to pharmaceuticals; Providing health information relating to pharmaceuticals; Providing health information relating to pharmaceuticals via a website; Providing medical information relating to pharmaceuticals via a website; Providing news and information in the field of medicine relating to pharmaceuticals; Providing on-line information, news and commentary in the field of health and wellness relating to pharmaceuticals; Providing health information; providing health information via a website; providing medical information via a website; providing medical information in the field of depression and treatments for depression; providing mental health information via a website; providing mental health and wellness information; providing news and information in the field of medicine; providing news and information in the field of mental health about depression and treatments for depression; providing on-line information, news and commentary in the field of health and wellness relating to depression and treatments for depression; Providing healthcare information in the field of migraines; Providing healthcare information in the field of migraines via a website
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Printed educational materials in the field of migraines Promoting public awareness of migraines Providing healthcare information in the field of migraines; Providing healthcare information in the field of migraines via a website
85.
COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
Described herein is a method of treating a neurological or psychiatric condition comprising administering a methylenedioxy derived designer drug or a benzofuran derived designer drug, to a mammal in need thereof. Also described herein use of a compound in the manufacture of a medicament for treating a neurological or psychiatric condition, wherein the compound is a methylene derived designer drug or a benzofuran derived designer drug.
A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 25/34 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance au tabac
Disclosed herein are compositions comprising an NSAID such as meloxicam or ibuprofen and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan or other triptan such as donitriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan or other triptan such as donitriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan or other triptan such as donitriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, depression, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, depression, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss.
93.
PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE
This disclosure relates to pharmaceutical compositions comprising bupropion and cysteine, and pharmaceutical dosage forms comprising bupropion and cysteine. The disclosure also relates to molecular complexes of bupropion and cysteine. These compositions and dosage forms may have improved stability of bupropion.
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
This disclosure relates to microparticles containing bupropion, e.g., microparticles having a particle diameter of about 50 µm to about 100 µm. These microparticles may be included in pharmaceutical compositions and/or dosage forms for treatment of various disease, such as depression.
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p. ex. chorée, dyskinésie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
09 - Appareils et instruments scientifiques et électriques
Produits et services
Downloadable cloud-based software for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders; Downloadable software in the nature of a mobile application for the purpose of tracking, managing and storing information related to medications and medication compliance, patient health, wellness and symptoms, and patient diseases and disorders
Disclosed herein is a method of treating migraine in patients with a history of inadequate response to prior migraine treatments comprising: selecting a patient who, for at least the past month: 1) has had 2 to 8 migraines per month, and 2a) according to the patient, is never or rarely comfortable enough with the patient's migraine medication to be able to plan daily activities, 2b) according to the patient, after taking migraine medication, the patient never or rarely feels in control of the patient's migraines enough so that the patient feels there will be no disruption in the patient's daily activities, 2c) has an mTOQ-4 score of 0, and/or 2d) has a history of depression; and administering a combination of 20 mg of meloxicam and 10 mg of rizatriptan to the patient during a migraine attack.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
36 - Services financiers, assurances et affaires immobilières
Produits et services
Management of pharmacy benefit programs featuring a medical
benefit co-pay card (term considered too vague by the
International Bureau - Rule 13 (2) (b) of the Regulations);
financial administration of patient assistance eligibility
programs featuring a pharmacy benefit co-pay card; providing
financial assistance in the form of prepaid co-pay cards to
patients for medical benefits.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
